Literature DB >> 17412636

A genotypic and phenotypic comparison of type III secretion profiles of Pseudomonas aeruginosa cystic fibrosis and bacteremia isolates.

David W Wareham1, Michael A Curtis.   

Abstract

The type III secretion system (TTSS) of Pseudomonas aeruginosa enables delivery of a number of toxins involved in the disruption of eukaryotic epithelial surfaces. Whilst the ability to secrete ExoS facilitates invasion and internalization, the secretion of ExoU mediates acute cytotoxicity. In order to determine any association with the ability to secrete these toxins with the nature and severity of human infection, the TTSS genotypes and phenotypes of 163 clinical isolates were determined by multiplex PCR and Western blotting. An exoS+/exoU- genotype was associated with chronic infection in patients with cystic fibrosis whilst an exoS-/exoU+ genotype was associated with strains isolated from blood. Secretion of the ExoU protein was more commonly seen in isolates obtained from blood, suggesting this ability may be important in the development of acute invasive infection. Detection of TTSS toxins in clinical material may be useful in targeting antimicrobial therapy or identifying individuals infected with aggressive strains of P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17412636     DOI: 10.1016/j.ijmm.2007.02.004

Source DB:  PubMed          Journal:  Int J Med Microbiol        ISSN: 1438-4221            Impact factor:   3.473


  17 in total

1.  Pathogenicity islands PAPI-1 and PAPI-2 contribute individually and synergistically to the virulence of Pseudomonas aeruginosa strain PA14.

Authors:  Ewan M Harrison; Melissa E K Carter; Shelley Luck; Hong-Yu Ou; Xinyi He; Zixin Deng; Chris O'Callaghan; Aras Kadioglu; Kumar Rajakumar
Journal:  Infect Immun       Date:  2010-02-01       Impact factor: 3.441

2.  Determinants for persistence of Pseudomonas aeruginosa in hospitals: interplay between resistance, virulence and biofilm formation.

Authors:  S J Kaiser; N T Mutters; A DeRosa; C Ewers; U Frank; F Günther
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-10-12       Impact factor: 3.267

3.  Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection.

Authors:  Carlos E Milla; James F Chmiel; Frank J Accurso; Donald R VanDevanter; Michael W Konstan; Geoffrey Yarranton; David E Geller
Journal:  Pediatr Pulmonol       Date:  2013-09-09

4.  PcrV antibody-antibiotic combination improves survival in Pseudomonas aeruginosa-infected mice.

Authors:  Y Song; M Baer; R Srinivasan; J Lima; G Yarranton; C Bebbington; S V Lynch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-12-21       Impact factor: 3.267

5.  Environmental reservoirs for exoS+ and exoU+ strains of Pseudomonas aeruginosa.

Authors:  Victoria Rutherford; Kelly Yom; Egon A Ozer; Olivia Pura; Ami Hughes; Katherine R Murphy; Laura Cudzilo; David Mitchell; Alan R Hauser
Journal:  Environ Microbiol Rep       Date:  2018-08       Impact factor: 3.541

6.  Clinical outcomes of type III Pseudomonas aeruginosa bacteremia.

Authors:  Ali A El-Solh; Angela Hattemer; Alan R Hauser; Ahmad Alhajhusain; Hardik Vora
Journal:  Crit Care Med       Date:  2012-04       Impact factor: 7.598

Review 7.  Role of Host and Bacterial Lipids in Pseudomonas aeruginosa Respiratory Infections.

Authors:  Pamella Constantino-Teles; Albane Jouault; Lhousseine Touqui; Alessandra Mattos Saliba
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

Review 8.  Association between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: a review.

Authors:  Teiji Sawa; Masaru Shimizu; Kiyoshi Moriyama; Jeanine P Wiener-Kronish
Journal:  Crit Care       Date:  2014-12-13       Impact factor: 9.097

9.  Pseudomonas aeruginosa population structure revisited.

Authors:  Jean-Paul Pirnay; Florence Bilocq; Bruno Pot; Pierre Cornelis; Martin Zizi; Johan Van Eldere; Pieter Deschaght; Mario Vaneechoutte; Serge Jennes; Tyrone Pitt; Daniel De Vos
Journal:  PLoS One       Date:  2009-11-13       Impact factor: 3.240

10.  ExoU activates NF-κB and increases IL-8/KC secretion during Pseudomonas aeruginosa infection.

Authors:  Carolina Diettrich Mallet de Lima; Teresa Cristina Calegari-Silva; Renata Meirelles Santos Pereira; Sabrina Alves de Oliveira Lima Santos; Ulisses Gazos Lopes; Maria-Cristina Maciel Plotkowski; Alessandra Mattos Saliba
Journal:  PLoS One       Date:  2012-07-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.